Published on 8 Apr 2024 on Seeking Alpha
Bristol Myers reports positive Phase 3 data for schizophrenia drug (NYSE:BMY)
Bristol Myers (BMY) reported positive interim data from a Phase 3 study of its drug KarXT in the...
Want to become a better investor?
Start tracking your investments with Statfolio
Sign up for free